Skip to content

CEO video statement. Q3 2025.

Expanding our R&D activities

Today we share Gubra’s Q3 2025 results, a quarter marked by the arrival of Markus Rohrwild as our new CEO and the expansion of our R&D activities. With key pipeline programmes advancing (UCN2) and ABBV-295 (GUBamy) serving as our model for future partnerships, we look forward to broadening our collaborations and further strengthening Gubra’s role as a leading peptide-centric techbio company.

We invite you to read the full press release and to watch this interview with Markus Rohrwild in which he shares some reflections on his arrival at Gubra and his ambitions for the company. 

Share this page

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

[email protected]
+45 3152 ­2650

Back To Top